Improved Pathologic Diagnosis—Forecasting the Future in Glioblastoma
Main Authors: | David J. Pisapia, Rajiv Magge, Rohan Ramakrishna |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-12-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2017.00707/full |
Similar Items
-
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
by: Combs Stephanie E, et al.
Published: (2011-09-01) -
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
by: Yusuke Funakoshi, et al.
Published: (2021-05-01) -
CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS
by: M. V. Matsko, et al.
Published: (2021-06-01) -
Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping
by: James F. Lyon, et al.
Published: (2021-06-01) -
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-Like Cells
by: Brandner, S., et al.
Published: (2022)